Valuation: PureTech Health plc

Market Cap 427M 375M 345M 321M 606M 40.64B 619M 4.15B 1.61B 19.92B 1.6B 1.57B 69.35B P/E 2026 *
-3.82x
P/E 2027 * -4.24x
Enterprise Value 188M 165M 152M 142M 268M 17.93B 273M 1.83B 709M 8.79B 707M 691M 30.6B EV / Sales 2026 *
26.5x
EV / Sales 2027 * 14.4x
Free-Float
84.5%
Yield 2026 *
-
Yield 2027 * -
1 day-3.93%
Current month-3.93%
1 month-4.90%
3 months+22.22%
6 months+5.60%
Current year+5.60%
1 week 127.6
Extreme 127.6
140.02
1 month 121.6
Extreme 121.6016
140.02
Current year 107.4
Extreme 107.4
143.6
1 year 104.71
Extreme 104.712
148
3 years 100.4
Extreme 100.4
238.5
5 years 100.4
Extreme 100.4
410.66
10 years 100.4
Extreme 100.4
447.66
Manager TitleAgeSince
Chief Executive Officer 43 2025-07-14
President 53 2024-04-08
Chief Operating Officer - 2021-07-31
Director TitleAgeSince
Director/Board Member 76 2015-05-07
Director/Board Member 76 2008-12-31
Director/Board Member 73 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
03-12Buy

Founder

112,509 0.0466%
25-09-23Buy

Chairman

65,250 0.0272%
25-09-23Buy

Director

59,100 0.0246%
Change 5-day change 1-year change 3-year change Capi.($)
-3.93%0.00%+5.94%-39.31% 444M
+3.08%+9.20%-0.42%+5.47% 47.18B
+0.12%+10.62%+409.68%+600.97% 39.82B
+5.17%+18.64%+28.94%-9.60% 32.25B
+2.02%+5.29%+20.11%+63.06% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
+0.40%+12.24% - - 16.57B
+2.64%+14.80%+73.19%+126.33% 15.12B
-0.15%+4.94%+13.27%+17.71% 13.69B
-0.13%+4.21%+100.43%+93.01% 13.1B
Average +0.99%+7.04%+73.99%+98.72% 23.44B
Weighted average by Cap. +1.87%+7.40%+95.62%+137.64%

Financials

2026 *2027 *
Net sales 7.1M 6.24M 5.75M 5.35M 10.09M 676M 10.3M 69.05M 26.75M 331M 26.66M 26.07M 1.15B 13.47M 11.84M 10.9M 10.14M 19.14M 1.28B 19.54M 131M 50.75M 629M 50.57M 49.45M 2.19B
Net income -124M -109M -101M -93.73M -177M -11.85B -181M -1.21B -469M -5.81B -467M -457M -20.23B -97.27M -85.49M -78.72M -73.25M -138M -9.26B -141M -946M -367M -4.54B -365M -357M -15.81B
Net Debt -238M -210M -193M -180M -339M -22.7B -346M -2.32B -898M -11.13B -895M -876M -38.75B -232M -204M -188M -175M -330M -22.12B -337M -2.26B -875M -10.84B -872M -853M -37.75B
Logo PureTech Health plc
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
Employees
90
Date Price Change Volume
26-07-01 GBX 132.00 -3.93% 267,576
26-06-30 GBX 137.40 +2.54% 888,297
26-06-29 GBX 134.00 +2.13% 445,627
26-06-26 GBX 131.20 -0.30% 202,200
26-06-25 GBX 131.60 -1.94% 474,718
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.753USD
Average target price
5.151USD
Spread / Average Target
+193.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTC Stock